Harvard Bioscience, Inc. (HBIO) stock declined over -0.14%, trading at $2.49 on NASDAQ, down from the previous close of $2.49. The stock opened at $2.50, fluctuating between $2.46 and $2.53 in the recent session.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
Employees | 391 |
Beta | 1.296 |
Sales or Revenue | $112.25M |
5Y Sales Change% | -0.215% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Medical - Instruments & Supplies |
Harvard Bioscience, Inc. (NASDAQ: HBIO) stock price is $2.49 in the last trading session. During the trading session, HBIO stock reached the peak price of $2.53 while $2.46 was the lowest point it dropped to. The percentage change in HBIO stock occurred in the recent session was -0.14% while the dollar amount for the price change in HBIO stock was -$0.00.
The NASDAQ listed HBIO is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector. Harvard Bioscience, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Jennifer Cote C.P.A., CGMA
Chief Financial Officer & Treasurer
Mr. Kenneth Fletcher Olson
Executive Officer
David Sirois
Director of Corporation Accounting & SEC Reporting
Mr. Michael A. Rossi
Chief Financial Officer & Treasurer
Jennifer Cote
Interim Chief Financial Officer & Treasurer
Mr. John J. Fry
Chief Legal Counsel & Corporation Sec.
Mr. Ryan Wallace
Senior Vice President of Global Sales - Preclinical Systems
Mr. James W. Green
Pres, Chief Executive Officer & Chairman
Ms. Jennifer Cote CPA, CGMA
Chief Financial Officer & Treasurer
Mr. David Balcom
Senior Vice President of Operations
Ms. Lori Packer
Vice President of Global People Operations
HBIO's closing price is 7.33% higher than its 52-week low of $2.32 where as its distance from 52-week high of $5.56 is -55.22%.
Number of HBIO employees currently stands at 391.
Official Website of HBIO is: https://www.harvardbioscience.com
HBIO could be contacted at phone 508 893 8999 and can also be accessed through its website. HBIO operates from 84 October Hill Road, Holliston, MA 01746, United States.
HBIO stock volume for the day was 19.9K shares. The average number of HBIO shares traded daily for last 3 months was 110.2K.
The market value of HBIO currently stands at $108.44M with its latest stock price at $2.49 and 43.61M of its shares outstanding.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com